Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-10-06

AUTHORS

André R. Durães, Yasmin de Souza Lima Bitar, José Admirço L. Filho, Igor S. Schonhofen, Edmundo J. N. Camara, Leonardo Roever, Hugo E. D. P. Cardoso, Kevan M. Akrami

ABSTRACT

INTRODUCTION: Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult, therefore new alternatives need to be evaluated. METHODS: RIWA is a phase II/III, prospective, open-label, randomized, pilot study designed to investigate oral rivaroxaban 15 mg twice daily compared with dose-adjusted warfarin for the prevention of stroke (ischemic or hemorrhagic) and systemic embolism in patients with MHV, from August 2018 to December 2019. Patients will undergo transesophageal echocardiography at the beginning and the end of the study (follow-up time 90 days). On an explanatory basis, all events will be analyzed, including stroke, peripheral systemic embolism, valve thrombosis, significant bleeding and death. DISCUSSION: Warfarin and similar VKAs are standard therapy for patients with an MHV. Even with the appropriate use of therapy, the incidence of thromboembolic events is high at 1-4% per year. Furthermore, bleeding risk is significant, ranging from 2 to 9% per year. The new frontier to be overcome in relation to use of the new oral anticoagulants is undoubtedly in patients with MHV. A significant portion of people with MHV worldwide will benefit if noninferiority of these new agents is confirmed. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03566303. Recruitment Status: Recruiting. First Posted: 25 June 2018. Last Update Posted: 25 June 2018. More... »

PAGES

303-308

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-018-0249-5

DOI

http://dx.doi.org/10.1007/s40268-018-0249-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107437522

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30293126


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiac Surgical Procedures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase I as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase II as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Echocardiography, Transesophageal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Valve Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Valves", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rivaroxaban", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "General Hospital Roberto Santos, Salvador, Bahia Brazil", 
            "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dur\u00e3es", 
        "givenName": "Andr\u00e9 R.", 
        "id": "sg:person.0616265726.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616265726.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Souza Lima Bitar", 
        "givenName": "Yasmin", 
        "id": "sg:person.014060572774.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014060572774.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "General Hospital Roberto Santos, Salvador, Bahia Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "General Hospital Roberto Santos, Salvador, Bahia Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Filho", 
        "givenName": "Jos\u00e9 Admir\u00e7o L.", 
        "id": "sg:person.012154012670.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012154012670.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "General Hospital Roberto Santos, Salvador, Bahia Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "General Hospital Roberto Santos, Salvador, Bahia Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schonhofen", 
        "givenName": "Igor S.", 
        "id": "sg:person.011356432270.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011356432270.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Camara", 
        "givenName": "Edmundo J. N.", 
        "id": "sg:person.0757601270.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757601270.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia, Minas Gerais Brazil", 
          "id": "http://www.grid.ac/institutes/grid.411284.a", 
          "name": [
            "Federal University of Uberl\u00e2ndia, Uberl\u00e2ndia, Minas Gerais Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roever", 
        "givenName": "Leonardo", 
        "id": "sg:person.01170504610.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170504610.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "General Hospital Roberto Santos, Salvador, Bahia Brazil", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "General Hospital Roberto Santos, Salvador, Bahia Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cardoso", 
        "givenName": "Hugo E. D. P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Infectious Disease, Department of Medicine, University of California, San Diego, San Diego, CA USA", 
          "id": "http://www.grid.ac/institutes/grid.266100.3", 
          "name": [
            "Division of Infectious Disease, Department of Medicine, University of California, San Diego, San Diego, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Akrami", 
        "givenName": "Kevan M.", 
        "id": "sg:person.01340755134.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340755134.94"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11239-011-0621-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050077821", 
          "https://doi.org/10.1007/s11239-011-0621-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-10-06", 
    "datePublishedReg": "2018-10-06", 
    "description": "INTRODUCTION: Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult, therefore new alternatives need to be evaluated.\nMETHODS: RIWA is a phase II/III, prospective, open-label, randomized, pilot study designed to investigate oral rivaroxaban 15\u00a0mg twice daily compared with dose-adjusted warfarin for the prevention of stroke (ischemic or hemorrhagic) and systemic embolism in patients with MHV, from August 2018 to December 2019. Patients will undergo transesophageal echocardiography at the beginning and the end of the study (follow-up time 90\u00a0days). On an explanatory basis, all events will be analyzed, including stroke, peripheral systemic embolism, valve thrombosis, significant bleeding and death.\nDISCUSSION: Warfarin and similar VKAs are standard therapy for patients with an MHV. Even with the appropriate use of therapy, the incidence of thromboembolic events is high at 1-4% per year. Furthermore, bleeding risk is significant, ranging from 2 to 9% per year. The new frontier to be overcome in relation to use of the new oral anticoagulants is undoubtedly in patients with MHV. A significant portion of people with MHV worldwide will benefit if noninferiority of these new agents is confirmed.\nTRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03566303. Recruitment Status: Recruiting. First Posted: 25 June 2018. Last Update Posted: 25 June 2018.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-018-0249-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "vitamin K antagonists", 
      "mechanical heart valves", 
      "systemic embolism", 
      "thromboembolic events", 
      "phase II/III", 
      "dose-adjusted warfarin", 
      "new oral anticoagulants", 
      "prevention of stroke", 
      "heart valves", 
      "rivaroxaban 15", 
      "oral anticoagulants", 
      "significant bleeding", 
      "standard therapy", 
      "therapeutic options", 
      "transesophageal echocardiography", 
      "clinical management", 
      "drug classes", 
      "new agents", 
      "patients", 
      "warfarin", 
      "pilot study", 
      "embolism", 
      "appropriate use", 
      "therapy", 
      "stroke", 
      "anticoagulation", 
      "bleeding", 
      "echocardiography", 
      "thrombosis", 
      "noninferiority", 
      "anticoagulants", 
      "antagonist", 
      "years", 
      "valve", 
      "permanent use", 
      "incidence", 
      "study", 
      "prevention", 
      "death", 
      "events", 
      "risk", 
      "use", 
      "options", 
      "new alternative", 
      "agents", 
      "rationale", 
      "management", 
      "new frontier", 
      "significant portion", 
      "people", 
      "portion", 
      "alternative", 
      "end", 
      "beginning", 
      "basis", 
      "explanatory basis", 
      "relation", 
      "identifiers", 
      "class", 
      "design", 
      "frontier", 
      "K antagonists", 
      "RIWA", 
      "II/III", 
      "oral rivaroxaban 15", 
      "peripheral systemic embolism", 
      "similar VKAs", 
      "NCT03566303", 
      "RIWA Study"
    ], 
    "name": "Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study", 
    "pagination": "303-308", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107437522"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-018-0249-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30293126"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-018-0249-5", 
      "https://app.dimensions.ai/details/publication/pub.1107437522"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_781.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-018-0249-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0249-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0249-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0249-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0249-5'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      22 PREDICATES      114 URIs      105 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-018-0249-5 schema:about N0c3666a8bc8f42eba2deca651c0cd5fc
2 N1ff5f94d97694ffca058f0c48f58e985
3 N205e13fe0c564d4c8336ad9dce4564d2
4 N23f503db98ed4f9abfaf5f1e76d30b61
5 N2593f5203689456bad167b3a0c9d663c
6 N26f182f2e2194a0986d95de05b9de6c9
7 N3356ccfe1a8c4ac6a17be1b491561606
8 N6085f2853d7b49ebaafc67e91f2bd076
9 N61f800978e384e83a335dc0a1e42a21a
10 N6f9a8596ab9b41db915537b63a426ba4
11 N87ce1a0cc00f4109a668bb0c53721bd6
12 Nb454725718694380a5c6a0e5bd5c74b8
13 Nbdd5397bcba748eea74183f42c80e5e8
14 Ncb7be0c589c04b558bfe43d8c7fdba3e
15 Nd1a493dafc824a1e97ac4cdbbbbc30eb
16 Nd83aa1b5df2f4fb5bbf8d6b1a8d98a56
17 Ne1b91fa8b9b04e53b35538f6b74111f3
18 Nf60bf38095804b7c8d13256094e1da85
19 anzsrc-for:11
20 anzsrc-for:1102
21 schema:author N42404061727b41c7987df53771c1c39e
22 schema:citation sg:pub.10.1007/s11239-011-0621-6
23 schema:datePublished 2018-10-06
24 schema:datePublishedReg 2018-10-06
25 schema:description INTRODUCTION: Mechanical heart valves (MHV) are extremely durable, but they require permanent use of anticoagulation to prevent thromboembolic events. The only approved therapeutic options are vitamin K antagonists (VKAs), such as warfarin. As a drug class, clinical management is difficult, therefore new alternatives need to be evaluated. METHODS: RIWA is a phase II/III, prospective, open-label, randomized, pilot study designed to investigate oral rivaroxaban 15 mg twice daily compared with dose-adjusted warfarin for the prevention of stroke (ischemic or hemorrhagic) and systemic embolism in patients with MHV, from August 2018 to December 2019. Patients will undergo transesophageal echocardiography at the beginning and the end of the study (follow-up time 90 days). On an explanatory basis, all events will be analyzed, including stroke, peripheral systemic embolism, valve thrombosis, significant bleeding and death. DISCUSSION: Warfarin and similar VKAs are standard therapy for patients with an MHV. Even with the appropriate use of therapy, the incidence of thromboembolic events is high at 1-4% per year. Furthermore, bleeding risk is significant, ranging from 2 to 9% per year. The new frontier to be overcome in relation to use of the new oral anticoagulants is undoubtedly in patients with MHV. A significant portion of people with MHV worldwide will benefit if noninferiority of these new agents is confirmed. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03566303. Recruitment Status: Recruiting. First Posted: 25 June 2018. Last Update Posted: 25 June 2018.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N5c2fd0898f3c42919951d33d1bff015a
30 Ne46ba12cb3eb45eabe31569387dd0255
31 sg:journal.1020803
32 schema:keywords II/III
33 K antagonists
34 NCT03566303
35 RIWA
36 RIWA Study
37 agents
38 alternative
39 antagonist
40 anticoagulants
41 anticoagulation
42 appropriate use
43 basis
44 beginning
45 bleeding
46 class
47 clinical management
48 death
49 design
50 dose-adjusted warfarin
51 drug classes
52 echocardiography
53 embolism
54 end
55 events
56 explanatory basis
57 frontier
58 heart valves
59 identifiers
60 incidence
61 management
62 mechanical heart valves
63 new agents
64 new alternative
65 new frontier
66 new oral anticoagulants
67 noninferiority
68 options
69 oral anticoagulants
70 oral rivaroxaban 15
71 patients
72 people
73 peripheral systemic embolism
74 permanent use
75 phase II/III
76 pilot study
77 portion
78 prevention
79 prevention of stroke
80 rationale
81 relation
82 risk
83 rivaroxaban 15
84 significant bleeding
85 significant portion
86 similar VKAs
87 standard therapy
88 stroke
89 study
90 systemic embolism
91 therapeutic options
92 therapy
93 thromboembolic events
94 thrombosis
95 transesophageal echocardiography
96 use
97 valve
98 vitamin K antagonists
99 warfarin
100 years
101 schema:name Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study
102 schema:pagination 303-308
103 schema:productId N7202230c99814c529fff008d6d2d8e9c
104 Nb2d72250b4cc41bb8edfa21dee04be5a
105 Nb71f9eb47a11445c8fdb32793ab29cd6
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107437522
107 https://doi.org/10.1007/s40268-018-0249-5
108 schema:sdDatePublished 2021-12-01T19:42
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher Nd8ecafffdd22466385c672c3309ca33a
111 schema:url https://doi.org/10.1007/s40268-018-0249-5
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N0c3666a8bc8f42eba2deca651c0cd5fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Warfarin
117 rdf:type schema:DefinedTerm
118 N1ff5f94d97694ffca058f0c48f58e985 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Adult
120 rdf:type schema:DefinedTerm
121 N205e13fe0c564d4c8336ad9dce4564d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Adolescent
123 rdf:type schema:DefinedTerm
124 N23f503db98ed4f9abfaf5f1e76d30b61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Clinical Trials, Phase I as Topic
126 rdf:type schema:DefinedTerm
127 N2593f5203689456bad167b3a0c9d663c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged
129 rdf:type schema:DefinedTerm
130 N26f182f2e2194a0986d95de05b9de6c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Pilot Projects
132 rdf:type schema:DefinedTerm
133 N3356ccfe1a8c4ac6a17be1b491561606 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Cardiac Surgical Procedures
135 rdf:type schema:DefinedTerm
136 N42404061727b41c7987df53771c1c39e rdf:first sg:person.0616265726.51
137 rdf:rest N6b70ea3383504209948599774bf6c0ec
138 N5c2fd0898f3c42919951d33d1bff015a schema:issueNumber 4
139 rdf:type schema:PublicationIssue
140 N6085f2853d7b49ebaafc67e91f2bd076 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Echocardiography, Transesophageal
142 rdf:type schema:DefinedTerm
143 N61f800978e384e83a335dc0a1e42a21a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Middle Aged
145 rdf:type schema:DefinedTerm
146 N6404746ad0444cc78461de08318024b5 rdf:first sg:person.011356432270.81
147 rdf:rest Nc5fe5ec7618740ddbfef65df08067d6e
148 N6b70ea3383504209948599774bf6c0ec rdf:first sg:person.014060572774.12
149 rdf:rest N77d80f3c9da3492d811a69c8903fff61
150 N6f9a8596ab9b41db915537b63a426ba4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Heart Valves
152 rdf:type schema:DefinedTerm
153 N7202230c99814c529fff008d6d2d8e9c schema:name dimensions_id
154 schema:value pub.1107437522
155 rdf:type schema:PropertyValue
156 N77d80f3c9da3492d811a69c8903fff61 rdf:first sg:person.012154012670.27
157 rdf:rest N6404746ad0444cc78461de08318024b5
158 N87ce1a0cc00f4109a668bb0c53721bd6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Young Adult
160 rdf:type schema:DefinedTerm
161 N91b70fecf1f64e08b74e25ee91d96bdf schema:affiliation grid-institutes:None
162 schema:familyName Cardoso
163 schema:givenName Hugo E. D. P.
164 rdf:type schema:Person
165 Nb2d72250b4cc41bb8edfa21dee04be5a schema:name pubmed_id
166 schema:value 30293126
167 rdf:type schema:PropertyValue
168 Nb454725718694380a5c6a0e5bd5c74b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Prospective Studies
170 rdf:type schema:DefinedTerm
171 Nb71f9eb47a11445c8fdb32793ab29cd6 schema:name doi
172 schema:value 10.1007/s40268-018-0249-5
173 rdf:type schema:PropertyValue
174 Nbdd5397bcba748eea74183f42c80e5e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Humans
176 rdf:type schema:DefinedTerm
177 Nc5fe5ec7618740ddbfef65df08067d6e rdf:first sg:person.0757601270.40
178 rdf:rest Nd4d5b457844b4388a7fce3d82e01bffa
179 Nc95612990d7e464caa9f2331ce6df02f rdf:first sg:person.01340755134.94
180 rdf:rest rdf:nil
181 Ncb7be0c589c04b558bfe43d8c7fdba3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Rivaroxaban
183 rdf:type schema:DefinedTerm
184 Nd1a493dafc824a1e97ac4cdbbbbc30eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Heart Valve Diseases
186 rdf:type schema:DefinedTerm
187 Nd4d5b457844b4388a7fce3d82e01bffa rdf:first sg:person.01170504610.87
188 rdf:rest Nf746307ce02f40b18bd88cf4f8791b4b
189 Nd83aa1b5df2f4fb5bbf8d6b1a8d98a56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Clinical Trials, Phase II as Topic
191 rdf:type schema:DefinedTerm
192 Nd8ecafffdd22466385c672c3309ca33a schema:name Springer Nature - SN SciGraph project
193 rdf:type schema:Organization
194 Ne1b91fa8b9b04e53b35538f6b74111f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Anticoagulants
196 rdf:type schema:DefinedTerm
197 Ne46ba12cb3eb45eabe31569387dd0255 schema:volumeNumber 18
198 rdf:type schema:PublicationVolume
199 Nf60bf38095804b7c8d13256094e1da85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Randomized Controlled Trials as Topic
201 rdf:type schema:DefinedTerm
202 Nf746307ce02f40b18bd88cf4f8791b4b rdf:first N91b70fecf1f64e08b74e25ee91d96bdf
203 rdf:rest Nc95612990d7e464caa9f2331ce6df02f
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
208 schema:name Cardiorespiratory Medicine and Haematology
209 rdf:type schema:DefinedTerm
210 sg:journal.1020803 schema:issn 1174-5886
211 1179-6901
212 schema:name Drugs in R&D
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.011356432270.81 schema:affiliation grid-institutes:None
216 schema:familyName Schonhofen
217 schema:givenName Igor S.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011356432270.81
219 rdf:type schema:Person
220 sg:person.01170504610.87 schema:affiliation grid-institutes:grid.411284.a
221 schema:familyName Roever
222 schema:givenName Leonardo
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170504610.87
224 rdf:type schema:Person
225 sg:person.012154012670.27 schema:affiliation grid-institutes:None
226 schema:familyName Filho
227 schema:givenName José Admirço L.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012154012670.27
229 rdf:type schema:Person
230 sg:person.01340755134.94 schema:affiliation grid-institutes:grid.266100.3
231 schema:familyName Akrami
232 schema:givenName Kevan M.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340755134.94
234 rdf:type schema:Person
235 sg:person.014060572774.12 schema:affiliation grid-institutes:None
236 schema:familyName de Souza Lima Bitar
237 schema:givenName Yasmin
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014060572774.12
239 rdf:type schema:Person
240 sg:person.0616265726.51 schema:affiliation grid-institutes:None
241 schema:familyName Durães
242 schema:givenName André R.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616265726.51
244 rdf:type schema:Person
245 sg:person.0757601270.40 schema:affiliation grid-institutes:None
246 schema:familyName Camara
247 schema:givenName Edmundo J. N.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757601270.40
249 rdf:type schema:Person
250 sg:pub.10.1007/s11239-011-0621-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050077821
251 https://doi.org/10.1007/s11239-011-0621-6
252 rdf:type schema:CreativeWork
253 grid-institutes:None schema:alternateName Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil
254 General Hospital Roberto Santos, Salvador, Bahia Brazil
255 schema:name Federal University of Bahia, Medical School-UFBA/FAMEB, XV de novembro Square, s/n-Largo do Terreiro de Jesus, Salvador, BA 40025-010 Brazil
256 General Hospital Roberto Santos, Salvador, Bahia Brazil
257 rdf:type schema:Organization
258 grid-institutes:grid.266100.3 schema:alternateName Division of Infectious Disease, Department of Medicine, University of California, San Diego, San Diego, CA USA
259 schema:name Division of Infectious Disease, Department of Medicine, University of California, San Diego, San Diego, CA USA
260 rdf:type schema:Organization
261 grid-institutes:grid.411284.a schema:alternateName Federal University of Uberlândia, Uberlândia, Minas Gerais Brazil
262 schema:name Federal University of Uberlândia, Uberlândia, Minas Gerais Brazil
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...